425 related articles for article (PubMed ID: 16943686)
1. DNA flow cytometry but not telomerase activity as predictor of disease-free survival in pT1-2/N0/G2 breast cancer.
Pinto AE; André S; Pereira T; Silva G; Soares J
Pathobiology; 2006; 73(2):63-70. PubMed ID: 16943686
[TBL] [Abstract][Full Text] [Related]
2. Combined flow cytometry determination of S-phase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: analysis of a series of 271 patients with stage I and II breast cancer.
Moureau-Zabotto L; Bouchet C; Cesari D; Uzan S; Lefranc JP; Antoine M; Genestie C; Deniaud-Alexandre E; Bernaudin JF; Touboul E; Fleury-Feith J
Breast Cancer Res Treat; 2005 May; 91(1):61-71. PubMed ID: 15868432
[TBL] [Abstract][Full Text] [Related]
3. DNA ploidy is an independent predictor of survival in breast invasive ductal carcinoma: a long-term multivariate analysis of 393 patients.
Pinto AE; Pereira T; Santos M; Branco M; Dias A; Silva GL; Ferreira MC; André S
Ann Surg Oncol; 2013 May; 20(5):1530-7. PubMed ID: 23250736
[TBL] [Abstract][Full Text] [Related]
4. [Combined flow cytometry determination of S-phase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: review of a series of 271 patients with stage I and II breast cancer].
Moureau-Zabotto L; Bouchet C; Cesari D; Uzan S; Lefranc JP; Antoine M; Genestie C; Deniaud-Alexandre E; Bernaudin JF; Touboul E; Fleury-Feith J
Cancer Radiother; 2005 Dec; 9(8):575-86. PubMed ID: 16243560
[TBL] [Abstract][Full Text] [Related]
5. S-phase fraction and DNA ploidy in 633 T1T2 breast cancers: a standardized flow cytometric study.
Chassevent A; Jourdan ML; Romain S; Descotes F; Colonna M; Martin PM; Bolla M; Spyratos F
Clin Cancer Res; 2001 Apr; 7(4):909-17. PubMed ID: 11309341
[TBL] [Abstract][Full Text] [Related]
6. Sex steroid receptors, S-phase fraction and DNA ploidy as determinants of the risk of relapse and death of female breast cancer.
Lipponen P; Eskelinen M; Papinaho S; Klemi PJ; Aaltomaa S; Kosma VM; Marin S; Syrjänen K
Anticancer Res; 1992; 12(3):677-82. PubMed ID: 1622125
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of DNA image cytometry in Libyan breast cancer.
Ermiah E; Abdalla F; Buhmeida A; Alshrad M; Salem N; Pyrhönen S; Collan Y
Oncology; 2012; 83(3):165-76. PubMed ID: 22906963
[TBL] [Abstract][Full Text] [Related]
8. C-erbB-2 oncoprotein overexpression identifies a subgroup of estrogen receptor positive (ER+) breast cancer patients with poor prognosis.
Pinto AE; André S; Pereira T; Nóbrega S; Soares J
Ann Oncol; 2001 Apr; 12(4):525-33. PubMed ID: 11398888
[TBL] [Abstract][Full Text] [Related]
9. S-phase fraction determined on fine needle aspirates is an independent prognostic factor in breast cancer - a multivariate study of 770 patients.
Gazic B; Pizem J; Bracko M; Cufer T; Borstnar S; Pohar-Marinsek Z; Us-Krasovec M
Cytopathology; 2008 Oct; 19(5):294-302. PubMed ID: 18070112
[TBL] [Abstract][Full Text] [Related]
10. [DNA ploidy is an independent prognostic biomarker in breast invasive ductal carcinoma].
Pinto AE; Pereira T; Silva GL; Ferreira MC; André S
Acta Med Port; 2012; 25(6):399-407. PubMed ID: 23534591
[TBL] [Abstract][Full Text] [Related]
11. Mutant p53 expression and DNA analysis in human breast cancer comparison with conventional clinicopathological parameters.
Rosanelli GP; Steindorfer P; Wirnsberger GH; Klimpfinger M; Ratschek M; Puerstner P; Auner H; Berhold A
Anticancer Res; 1995; 15(2):581-6. PubMed ID: 7763041
[TBL] [Abstract][Full Text] [Related]
12. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
13. Comparative long-term prognostic value of quantitative HER-2/neu protein expression, DNA ploidy, and morphometric and clinical features in paraffin-embedded invasive breast cancer.
Baak JP; Chin D; van Diest PJ; Ortiz R; Matze-Cok P; Bacus SS
Lab Invest; 1991 Feb; 64(2):215-23. PubMed ID: 1671789
[TBL] [Abstract][Full Text] [Related]
14. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
[TBL] [Abstract][Full Text] [Related]
15. Ploidy and S-phase fraction as predictive markers of response to radiotherapy in cervical cancer.
Pinto AE; Pires A; Silva G; Bicho C; André S; Soares J
Pathol Res Pract; 2011 Oct; 207(10):623-7. PubMed ID: 21940107
[TBL] [Abstract][Full Text] [Related]
16. Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression.
Poller DN; Silverstein MJ; Galea M; Locker AP; Elston CW; Blamey RW; Ellis IO
Mod Pathol; 1994 Feb; 7(2):257-62. PubMed ID: 7911998
[TBL] [Abstract][Full Text] [Related]
17. Flow cytometry in node-positive breast cancer: cancer and leukemia group B protocol 8869.
Kute TE; Quadri Y; Muss H; Zbieranski N; Cirrincione C; Berry DA; Barcos M; Thor AP; Liu E; Koerner F
Cytometry; 1995 Dec; 22(4):297-306. PubMed ID: 8749780
[TBL] [Abstract][Full Text] [Related]
18. Aneuploidy identifies subsets of patients with poor clinical outcome in grade 1 and grade 2 breast cancer.
Pinto AE; Pereira T; Silva GL; André S
Breast; 2015 Aug; 24(4):449-55. PubMed ID: 25920680
[TBL] [Abstract][Full Text] [Related]
19. S-phase fraction and menopausal status as the most important prognostic factors of disease-free survival for node negative patients with breast cancer. A prospective study.
Lackowska B; Niezabitowski A; Ryś J; Skołyszewski J; Stelmach A; Gruchała A; Jaszcz-Gruchała A
Pol J Pathol; 2003; 54(2):101-10. PubMed ID: 14575418
[TBL] [Abstract][Full Text] [Related]
20. Flow cytometric S-phase fraction as a complementary biological parameter for the cytological grading of non-Hodgkin's lymphoma.
Pinto AE; Cabeçadas J; Nóbrega SD; Mendonça E
Diagn Cytopathol; 2003 Oct; 29(4):194-9. PubMed ID: 14506670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
